Zacks Research Predicts Exelixis’ Q1 Earnings (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at Zacks Research upped their Q1 2026 earnings per share estimates for shares of Exelixis in a research report issued on Friday, February 6th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $0.65 per share for the quarter, up from their prior estimate of $0.61. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q2 2026 earnings at $0.68 EPS, FY2026 earnings at $2.91 EPS, Q1 2027 earnings at $0.80 EPS, Q3 2027 earnings at $0.97 EPS, Q4 2027 earnings at $1.12 EPS and FY2027 earnings at $3.84 EPS.

A number of other research firms have also recently commented on EXEL. Citigroup cut shares of Exelixis from a “market outperform” rating to an “underperform” rating in a research note on Monday, January 5th. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Barclays upped their target price on Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a research report on Wednesday. Wells Fargo & Company reduced their target price on Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 21st. Finally, Guggenheim cut Exelixis from a “buy” rating to a “neutral” rating in a research report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Exelixis currently has a consensus rating of “Hold” and a consensus price target of $46.16.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $43.90 on Monday. Exelixis has a fifty-two week low of $32.38 and a fifty-two week high of $49.62. The firm has a market cap of $11.77 billion, a price-to-earnings ratio of 18.52, a P/E/G ratio of 0.74 and a beta of 0.42. The firm has a fifty day moving average price of $43.69 and a 200 day moving average price of $40.95.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after purchasing an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after purchasing an additional 68,133 shares in the last quarter. Focus Partners Wealth grew its holdings in Exelixis by 83.4% in the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after purchasing an additional 17,483 shares during the period. Geneos Wealth Management Inc. increased its position in shares of Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 944 shares in the last quarter. Finally, Sivia Capital Partners LLC raised its stake in shares of Exelixis by 23.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after buying an additional 2,764 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Buying and Selling

In related news, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total value of $1,032,400.46. Following the completion of the transaction, the director directly owned 21,380 shares in the company, valued at $896,463.40. The trade was a 53.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Stelios Papadopoulos sold 100,000 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the sale, the director directly owned 1,189,228 shares in the company, valued at $51,790,879.40. This trade represents a 7.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 245,235 shares of company stock valued at $10,490,600. Insiders own 2.82% of the company’s stock.

Exelixis News Summary

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research upgraded Exelixis from a “hold” to a “strong‑buy,” signaling increased analyst conviction that the company’s growth story is improving. Read More.
• Positive Sentiment: Zacks issued broad upward revisions to Exelixis’ earnings outlook — raising FY2026 to $2.76 from $2.34 and FY2027 to $3.65 (previously $3.30), and lifting several quarterly estimates (e.g., Q1‑Q4 2026 and Q1‑Q4 2027). These higher forward EPS forecasts support a re‑rating and provide a clearer path to earnings growth. Read More.
• Positive Sentiment: Zacks published a bullish write‑up, “3 Reasons Why Growth Investors Shouldn’t Overlook Exelixis,” highlighting growth attributes that could help EXEL outperform — a narrative that can attract growth‑oriented buyers. Read More.
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating on EXEL, providing additional sell‑side support that may encourage institutional interest. Read More.
• Neutral Sentiment: Note that Zacks’ upgraded forecasts exceed the current broader consensus (the entries cite a consensus near $2.04 for the current year). The market may await confirmation from Exelixis’ upcoming results/sales trends before other analysts materially follow, which could create short‑term volatility. Read More.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.